Summary
To investigate the possible use of oral phosphate as an activator of bone remodeling in coherence treatment of osteoporosis, 82 postmenopausal females, aged 50–75 years, were randomized to treatment with oral phosphate (750, 1500, or 2550 mg/day) or placebo for 7 days and followed for 4 months thereafter. All patients had sustained at least one previous fracture of the distal forearm and had a bone mineral content of the contralateral forearm or bone mineral density of the lumbar spine lower than normal mean for age. Urinary phosphate/creatinine ratio increased in a dose-dependent fashion during treatment (P<0.001), whereas no significant changes were seen in serum phosphate or serum calcium. Serum parathyroid hormone (PTH) rose significantly (P<0.05) during treatment to a maximum of 36 and 33% in the groups receiving 1500 and 2250 mg/day, respectively, whereas serum 1,25-dihydroxycholecalciferol remained unchanged. In the group receiving 1500 mg/day, mean serum osteocalcin was increased in the period from day 1 to day 28 (P<0.05), but no significant changes were observed in urinary hydroxyproline/creatinine ratio, or serum bone alkaline phosphatase. We conclude that a short course of oral phosphate treatment increases serum PTH considerably. Furthermore, 1500 mg/day but not 2250 mg/day increases serum osteocalcin. No clear biochemical evidence, however, of increased activation of bone remodeling could be demonstrated in either group.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Meunier PJ, Bianchi GGS, Edouard CM, Bernard JC, Courpron P, Vignon GE (1972) Bony manifestations of thyrotoxicosis. Orthop Clin North Am 3:745–774
Frost HM (1979) Treatment of osteoporosis by manipulation of coherent bone cell populations. Clin Orthop Rel Res 143:227–244
Eriksen EF (1986) Normal and pathological remodeling of human trabecular bone: three-dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocrinol Rev 7:379–408
Hasling C, Eriksen EF, Charles P, Mosekilde L (1987) Exogenous triiodothyronine activates bone remodeling. Bone 8:65–69
Brixen K, Nielsen HK, Mosekilde L, Flyvbjerg A (1990) A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res 5:609–619
Hodsman AB, Fraher LJ (1990) Biochemical responses to sequential human parathyroid hormone (1–38) and calcitonin in osteoporotic patients. Bone Miner 9:137–152
Silverberg JS, Shane E, Clemens TL, Dempster DW, Segre GV, Lindsay R, Bilezikian JP (1986) The effect of oral phosphate administration on major indices of skeletal metabolism in normal subjects. J Bone Miner Res 1:383–388
Alexandre C, Chappard D, Caulin F, Bertrand A, Palle S, Riffat G (1988) Effects of a one-year administration of phosphate and intermittent calcitonin on bone-forming and bone-resorbing cells in involutional osteoporosis: a histomorphometric study. Calcif Tissue Int 42:345–350
Mallette LE, LeBlanc AD, Pool JL, Mechanick JI (1989) Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate. J Bone Miner Res 4:143–150
Rasmussen H, Bordier P, Auquier PML, Eisinger JB, Kuntz D, Caulin F, Argemi B, Gueris J, Julien A (1980) Effect of combined therapy with phosphate and calcitonin on bone volume in osteoporosis. Met Bone Dis Rel Res 2:107–111
Brixen K, Nielsen HK, Eriksen EF, Charles P, Mosekilde L (1989) Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone Gla-protein. Calcif Tissue Int 44:93–98
Price PA, Nishimoto SK (1980) Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci 77:2234–2238
Price PA, Otsuka AS, Poser JW, Kristaponis J, Raman N (1976) Characterization of a γ-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci USA 73:1447–1451
Keiding R, Hörder M, Gerhardt W, Pitkänen E, Tenhunen R, Strömme JH, Theodorsen L, Waldenström J, Tryding N, Westlund L (1974) Recommended methods for the determination of four enzymes in the blood. Scand J Clin Lab Invest 33:291–306
Rosalki SB, Foo AY (1984) Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. Clin Chem 30:1182–1186
Behr W, Barnert J (1986) Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: a simplified method and its clinical plausibility. Clin Chem 32:1960–1966
Mosekilde L, Charles P, Lindegreen P (1989) Determinants for serum 1,25-dihydroxycholecalciferol in primary hyperparathyroidism. Bone Miner 5:279–290
Lund B, Sørensen OH (1979) Measurements of 25-hydroxyvitamin D in serum and its relation to sunshine, age and vitamin D in the Danish population. Scand J Clin Lab Invest 39:23–30
Goverde BC, Veenkamp FJN (1972) Routine assay of total urinary hydroxyproline based on resin-catalysed hydrolysis. Clin Chimica Acta 41:29–40
Yamaoka K, Tanaka H, Kurose H, Shima M, Ozono K, Nakajima S, Seino Y (1989) Effect of single oral phosphate loading on vitamin D metabolites in normal subjects and in X-linked hypophosphatemic rickets. Bone Miner 7:159–169
Calvo MS, Kumar R, Heath H (1988) Elevated secretion and action of serum parathyroid hormone in young adults consuming high phosphorus, low calcium diets assembled from common foods. J Clin Endocrinol Metab 66:823–829
Calvo MS, Kumar R, Heath H (1990) Persistently elevated parathyroid hormone secretion and action in young women after 4 weeks of ingesting high phosphorus, low calcium diets. J Clin Endocrinol Metab 70:1334–1340
Tsai K, Ebeling PR, Riggs BL (1989) Bone responsiveness to parathyroid hormone in normal and osteoporotic women. J Clin Endocrinol Metab 1989;69:1024–1027
Beresford JN, Gallagher JA, Poser JW, Russell RGG (1984) Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, parathyroid hormone and glucocorticoids. Metab Bone Dis Res Res 5:229–234
Portale AA, Halloran BP, Murphy MM, Morris RC (1986) Oral intake of phosphorus can determine the serum concentration of 1,25 dihydroxy vitamin D by determining its production rate in human. J Clin Invest 77:7–12
Lian JB, Coutts M, Canalis E (1985) Studies on hormonal regulation of osteocalcin synthesis in cultured fetal rat calvaria. J Biol Chem 260:8706–8710
Riggs BL, Tsai KS, Mann KG (1984) Evidence that serum bone Gla-protein is a measure of bone formation but not of bone resorption. Calcif Tissue Int 36:497
Cole DEC, Gundberg CM (1985) Changes in serum osteocalcin associated with parathyroid hormone infusion in X-linked hypophosphatemic rickets. Clin Chim Acta 151:1–7
Charles P, Eriksen EF, Mosekilde L, Melsen F, Jensen FT (1987) Bone turnover and balance evaluated by a combined calcium balance and calcium kinetic study and dynamic histomorphometry. Metabolism 36:1118–1124
Raisz LG, Niemann I (1969) Effects of phosphate, calcium and magnesium on bone resorption and hormonal responses in tissue culture. Endocrinology 85:446–452
MacDonald BR, Gallagher JA, Russell RGG (1986) Parathyroid hormone stimulates the proliferation of cells derived from human bone. Endocrinology 118:2445–2449
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brixen, K., Nielsen, H.K., Charles, P. et al. Effects of a short course of oral phosphate treatment on serum parathyroid hormone (1–84) and biochemical markers of bone turnover: A dose-response study. Calcif Tissue Int 51, 276–281 (1992). https://doi.org/10.1007/BF00334487
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00334487